Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-4: camizestrant plus palbociclib versus anastrozole plus palbociclib in first-line ER-positive/HER2-negative advanced breast cancer
CTR20212607Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camizestrant, palbociclib, anastrozole in breast cancer, sponsored by AstraZeneca. Started Dec 2021; status: active.
02
Drugs
camizestrantpalbociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20212607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212607.